Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder

Nishiwaki, Hiroshi; Hamaguchi, Tetsuya; Ito, Mikako; Ishida, Tomohiro; Maeda, Tetsuya; Kashihara, Kenichi; Tsuboi, Yoshio; Ueyama, Jun; Shimamura, Teppei; Mori, Hiroshi; Kurokawa, Ken; Katsuno, Masahisa; Hirayama, Masaaki; Ohno, Kinji

doi:10.1128/msystems.00797-20

Cited by 71 publications

(62 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They identified 16 case-control studies concerning original gut microbiome data, and they agreed in the pathological imbalance between the microbial community in PD patients compared with HC. Additional studies [ 111 , 113 , 114 , 115 , 116 , 117 , 118 , 119 ] have been published since then and we have summarized all findings in Table 1 . At the phylum level, the increase of Proteobacteria, Actinobacteria , and Verrucomicrobia was reported in 4, 5, and 6 studies, respectively ( Table 1 ).…”

Section: Evidences For An Altered Gut–brain Axis In Parkinson’s DImentioning

confidence: 99%

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Lorente-Picón

Laguna

2021

Biomolecules

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut–brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.

show abstract

Section: Evidences For An Altered Gut–brain Axis In Parkinson’s DImentioning

confidence: 99%

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Lorente-Picón

Laguna

2021

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Akkermansia muciniphila (Akk bacteria) could degrade mucin, which is negatively related to inflammation and metabolic disorders [ 45 , 46 ]. It is demonstrated that genus Akkermansia and family Akkermansiaceae were consistently changed in both idiopathic rapid-eye-movement sleep behavior disorder and Parkinson’s disease [ 47 ]. In addition, microbial community profiling revealed reduction (e.g.…”

Section: Discussionmentioning

confidence: 99%

Assessing the effect of interaction between C-reactive protein and gut microbiome on the risks of anxiety and depression

et al. 2021

View full text Add to dashboard Cite

Cumulative evidence shows that gut microbiome can influence brain function and behavior via the inflammatory processes. However, the role of interaction between gut dysbiosis and C-reactive protein (CRP) in the development of anxiety and depression remains to be elucidated. In this study, a total of 3321 independent single nucleotide polymorphism (SNP) loci associated with gut microbiome were driven from genome-wide association study (GWAS). Using individual level genotype data from UK Biobank, we then calculated the polygenetic risk scoring (PRS) of 114 gut microbiome related traits. Moreover, regression analysis was conducted to evaluate the possible effect of interaction between gut microbiome and CRP on the risks of Patient Health Questionnaire-9 (PHQ-9) (N = 113,693) and Generalized Anxiety Disorder-7 (GAD-7) (N = 114,219). At last, 11 candidate CRP × gut microbiome interaction with suggestive significance was detected for PHQ-9 score, such as F_Ruminococcaceae (β = − 0.009, P = 2.2 × 10–3), G_Akkermansia (β = − 0.008, P = 7.60 × 10–3), F_Acidaminococcaceae (β = 0.008, P = 1.22 × 10–2), G_Holdemanella (β = − 0.007, P = 1.39 × 10–2) and O_Lactobacillales (β = 0.006, P = 1.79× 10–2). 16 candidate CRP × gut microbiome interaction with suggestive significance was detected for GAD-7 score, such as O_Bacteroidales (β = 0.010, P = 4.00× 10–4), O_Selenomonadales (β = − 0.010, P = 1.20 × 10–3), O_Clostridiales (β = 0.009, P = 2.70 × 10–3) and G_Holdemanella (β = − 0.008, P = 4.20 × 10–3). Our results support the significant effect of interaction between CRP and gut microbiome on the risks of anxiety and depression, and identified several candidate gut microbiomes for them.

show abstract

“…Akkermansia muciniphila (Akk bacteria) can also degrade mucin, which is negatively related to in ammation and metabolic disorders (39,40). It is demonstrated that genus Akkermansia and family Akkermansiaceae were consistently changed in both idiopathic rapid-eyemovement sleep behavior disorder and Parkinson's disease (41). In addition, microbial community pro ling revealed reduction (e.g.…”

Section: Discussionmentioning

confidence: 99%

Assessing the Effect of Interaction Between C-Reactive Protein and Gut Microbiome on the Risks of Anxiety and Depression

Chen

Meng

Cheng

et al. 2021

Preprint

View full text Add to dashboard Cite

Cumulative evidence shows that gut microbiome can influence brain function and behavior via the inflammatory processes. However, the role of interaction between gut dysbiosis and C-reactive protein (CRP) in the development of anxiety and depression remains to be elucidated. In this study, a total of 3,321 independent SNP loci associated with gut microbiome were driven from genome-wide association study (GWAS). Using individual level genotype data from UK Biobank, we then calculated the polygenetic risk scoring (PRS) of 114 gut microbiome related traits. Moreover, regression analysis was conducted to evaluate the possible effect of interaction between gut microbiome and CRP on the risks of Patient Health Questionnaire-9 (PHQ-9) (N = 113693) and Generalized Anxiety Disorder-7 (GAD-7) (N = 114219). At last, 11 candidate CRP× gut microbiome interacting were detected for PHQ-9 score, such as F_Ruminococcaceae (β=-0.009, P=2.2×10-3), G_Akkermansia (β=-0.008, P=7.60×10-3), F_Acidaminococcaceae (β=0.008, P=1.22×10-2), G_Holdemanella (β=-0.007, P=1.39×10-2) and O_Lactobacillales (β=0.006，P=1.79×10-2). 16 candidate CRP ×gut microbiome interacting were detected for GAD-7 score, such as O_Bacteroidales (β=0.010, P=4.00×10-4), O_Selenomonadales (β=-0.010, P=1.20×10-3), O_Clostridiales (β=0.009, P=2.70×10-3) and G_Holdemanella (β= -0.008, P=4.20×10-3). Our results support the significant effect of interaction between CRP and gut microbiome on the risks of anxiety and depression, and identified several candidate gut microbiome for them.

show abstract

Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder

Abstract: Twenty studies on gut microbiota in PD have been reported, whereas only one study has been reported on iRBD from Germany. iRBD has the highest likelihood ratio to develop PD. Our meta-analysis of iRBD in Japan and Germany revealed increased mucin-layer-degrading genus Akkermansia in iRBD.

Cited by 71 publications

References 94 publications

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota

Assessing the effect of interaction between C-reactive protein and gut microbiome on the risks of anxiety and depression

Assessing the Effect of Interaction Between C-Reactive Protein and Gut Microbiome on the Risks of Anxiety and Depression

Contact Info

Product

Resources

About